Advanced search
Publication Cover
Journal of Medical Economics Volume 24, 2021 - Issue 1
Submit an article Journal homepage
4,273
Views
11
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer

Elizabeth Thurgara BresMed Health Solutions Ltd, Sheffield, UK
,
Mark Gouldsona BresMed Health Solutions Ltd, Sheffield, UK
,
Suzette Matthijsseb BresMed Netherlands, Utrecht, The Netherlands
,
Mayur Amonkarc Merck & Co. Inc., Kenilworth, NJ, USA
,
Patricia Marinelloc Merck & Co. Inc., Kenilworth, NJ, USA
,
Navneet Upadhyayc Merck & Co. Inc., Kenilworth, NJ, USA
,
Chizoba Nwankwoc Merck & Co. Inc., Kenilworth, NJ, USA
&
Raquel Aguiar-Ibáñezd Merck Canada Inc., Kirkland, CanadaCorrespondence[email protected]
 show all
Pages 675-688 | Received 07 Oct 2020, Accepted 08 Apr 2021, Published online: 13 May 2021

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Blair McNamara, Yifan Chang, Levent Mutlu, Justin Harold & Alessandro D Santin. (2023) Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer. Expert Opinion on Biological Therapy 23:3, pages 227-233.
Read now

Articles from other publishers (10)

Kun Liu, Youwen Zhu, Yangying Zhou & Hong Zhu. (2023) Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis. Advances in Therapy 40:4, pages 1838-1849.
Crossref
Yuqiong Lu, Zhanjing Dai, Feng Chang, Li Wang, Jiafang He, Penghua Shi, Haitao Zhang & Yun Lu. (2023) Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment. PharmacoEconomics 41:3, pages 295-306.
Crossref
Yusuke Kajimoto, Kazunori Honda, Shiro Suzuki, Masahiko Mori, Hirofumi Tsubouchi, Kohshiro Nakao, Anri Azuma, Takashi Shibutani, Shoji Nagao, Takahiro Koyanagi, Izumi Kohara, Shuko Tamaki, Midori Yabuki, Lida Teng, Keiichi Fujiwara & Ataru Igarashi. (2023) Association between financial toxicity and health-related quality of life of patients with gynecologic cancer. International Journal of Clinical Oncology 28:3, pages 454-467.
Crossref
Shayan Dioun, Ling Chen, Alexander Melamed, Allison Gockley, Caryn M. St. Clair, June Y. Hou, Fady Khoury‐Collado, Chin Hur, Elena Elkin, Melissa Accordino, Dawn L. Hershman & Jason D. Wright. (2022) Dostarlimab for recurrent mismatch repair‐deficient endometrial cancer: A cost‐effectiveness study. BJOG: An International Journal of Obstetrics & Gynaecology 130:2, pages 214-221.
Crossref
Zhiwei Zheng, Liu Yang, Siqi Xu, Huide Zhu & Hongfu Cai. (2022) Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China. Frontiers in Pharmacology 13.
Crossref
Yusuke Kajimoto, Takashi Shibutani, Shoji Nagao, Satoshi Yamaguchi, Shiro Suzuki, Masahiko Mori, Hirofumi Tsubouchi, Kohshiro Nakao, Anri Azuma, Takahiro Koyanagi, Izumi Kohara, Shuko Tamaki, Midori Yabuki, Lida Teng, Kazunori Honda & Ataru Igarashi. (2022) Validity of the COmprehensive Score for financial Toxicity (COST) in patients with gynecologic cancer. International Journal of Gynecologic Cancer 32:9, pages 1189-1195.
Crossref
Kun Liu, Youwen Zhu, Yangying Zhou, Yu Zhang & Hong Zhu. (2022) Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis. Gynecologic Oncology 166:3, pages 582-588.
Crossref
Mingyang Feng, Yue Chen, Yang Yang & Qiu Li. (2022) Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis. Frontiers in Public Health 10.
Crossref
Yang Shi, Jigang Chen, Bo Shi & Aihua Liu. (2022) Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer. Gynecologic Oncology 164:2, pages 379-385.
Crossref
. (2021) Pembrolizumab in dMMR/MSI-H unresectable or metastatic endometrial cancer: substantial gain in life-years at acceptable cost in the US. PharmacoEconomics & Outcomes News 877:1, pages 16-16.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.